Ashwani Verma
Stock Analyst at UBS
(3.61)
# 778
Out of 5,173 analysts
106
Total ratings
48%
Success rate
7.12%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Neutral | $61 → $69 | $60.95 | +13.21% | 6 | Mar 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $655 → $705 | $521.22 | +35.26% | 12 | Mar 5, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $248 → $251 | $156.84 | +60.04% | 7 | Feb 24, 2026 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Neutral | $43 → $46 | $27.60 | +66.67% | 4 | Feb 11, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $127.05 | +40.10% | 11 | Jan 23, 2026 | |
| INSM Insmed | Maintains: Buy | $223 → $215 | $143.98 | +49.33% | 1 | Jan 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $40 | $20.99 | +90.57% | 9 | Jan 6, 2026 | |
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $33.63 | +182.49% | 1 | Dec 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $17.23 | +178.58% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $8.74 | +25.86% | 5 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $163 → $188 | $182.32 | +3.12% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $3.33 | +200.30% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $204.93 | +7.35% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $41.41 | -3.40% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $28.77 | -9.63% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $68 | $90.45 | -24.82% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $24.38 | -26.17% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $27.71 | +51.57% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.64 | -35.98% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $114.60 | -0.52% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $45.61 | -38.61% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $255.05 | -97.26% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $13.29 | -9.71% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.14 | +1,215.79% | 1 | Oct 11, 2022 |
Cytokinetics
Mar 6, 2026
Maintains: Neutral
Price Target: $61 → $69
Current: $60.95
Upside: +13.21%
United Therapeutics
Mar 5, 2026
Maintains: Buy
Price Target: $655 → $705
Current: $521.22
Upside: +35.26%
Axsome Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $248 → $251
Current: $156.84
Upside: +60.04%
Harmony Biosciences Holdings
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $27.60
Upside: +66.67%
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $127.05
Upside: +40.10%
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $143.98
Upside: +49.33%
ACADIA Pharmaceuticals
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $20.99
Upside: +90.57%
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $33.63
Upside: +182.49%
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $17.23
Upside: +178.58%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $8.74
Upside: +25.86%
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $182.32
Upside: +3.12%
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $3.33
Upside: +200.30%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $204.93
Upside: +7.35%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $41.41
Upside: -3.40%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $28.77
Upside: -9.63%
Jul 30, 2025
Maintains: Neutral
Price Target: $62 → $68
Current: $90.45
Upside: -24.82%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $24.38
Upside: -26.17%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $27.71
Upside: +51.57%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.64
Upside: -35.98%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $114.60
Upside: -0.52%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $45.61
Upside: -38.61%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $255.05
Upside: -97.26%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $13.29
Upside: -9.71%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.14
Upside: +1,215.79%